On Aug. 14, 2020, Medigen Vaccine Biologics (MBV) published preclinical results of their COVID-19 vaccine candidate in BioRxiv, a non-peer reviewed, open access preprint repository for the biological sciences.

In the studies conducted, the S-2P antigen was combined with various adjuvants to determine best immune response, administered to mice to test its ability in eliciting SARS-CoV-2 neutralizing antibodies, and administered to rats to investigate safety.